PDCD1 and neoplasm: Such combination treatment strongly blocks the PD-1/PD-L1 pathway, leading to elevation of pro-inflammatory anti-tumor responses such as higher infiltration and activity of NK cells and CD8+ cytotoxic cells and a diminished frequency of Treg cells.